根据美国证券交易委员会（SEC）最新披露的文件，生物制药公司Capricor Therapeutics已正式指控其合作伙伴Ns Pharma未能充分准备Deramiocel疗法的商业化上市工作，并涉嫌违反双方既定的合作协议。
该文件显示，Capricor方面认为Ns Pharma在推进细胞疗法Deramiocel的上市筹备过程中存在重大疏漏，未能履行协议约定的商业推广责任。此次纠纷可能对Deramiocel这一备受关注的创新疗法的市场推进计划产生直接影响。
目前双方尚未就此事发表进一步公开声明，但SEC文件的披露意味着相关法律程序可能已经启动。业界正密切关注这一商业纠纷的后续发展，特别是其对Deramiocel疗法上市时间表的潜在影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.